Ixekizumab is a recombinant humanized IgG4 monoclonal antibody that selectively binds to interleukin-17A (IL-17A), a proinflammatory cytokine pivotal in the pathogenesis of psoriasis [9]. This evidence concerns the gene IL17A and psoriasis.